創始團隊
創辦人暨首席醫療長 — 蘇加璐(Chia), MD, FACS
蘇博士現任加州大學洛杉磯分校（UCLA）整形外科系與骨科系教授兼研究副主任。她同時是臨床科學家、發明人及 FDA 法規專家，擁有超過二十年轉譯醫學研究經驗，並具備卓越的研究經費爭取能力。 蘇博士的臨床專長涵蓋慢性傷口治療與重建修復，並於 UCLA 傷口癒合與肢體保全中心及洛杉磯郡暨南加州大學醫學中心（LAC+USC）從事臨床與研究工作。蘇博士與丁博士共同擔任美國國家衛生研究院（NIH）多項計畫的負責人，累積獲得超過 3,000 萬美元研究經費，其中包含 1,400 萬美元的小型企業創新研究（SBIR）計畫，用於開發 SLI-F06 平台技術。
創辦人暨總裁 — 丁淦 (Eric), DMD, DMedSc
丁博士以優等（Magna Cum Laude）成績獲得哈佛大學牙科醫學博士（D.M.D.）與醫學科學博士（D.Med.Sc.）雙學位。曾任加州大學洛杉磯分校（UCLA）學術委員會教授暨生長與發展學系創始主任，並兼任醫學院及工程學院教授。丁博士亦曾在美國牙醫學會下屬的 Forsyth 研究所及台灣國立陽明交通大學牙醫學院任職，累積豐富的臨床與研究管理經驗。 作為組織工程與轉譯醫學領域的專家，丁博士已發表超過 140 篇國際期刊論文（包含《Nature Communications》、《Journal of Clinical Investigation》、《PLOS One》、《PNAS》、《Journal of Bone and Mineral Research》、《Biomaterials》等），累積引用超過 12,000 次，並擁有超過 78 件美國專利申請。 在生技產業中，丁博士協助新創公司籌募超過 4,000 萬美元資金，現任多家企業及醫療機構董事會成員，並擔任 Angelalign Technology 高級顧問。該公司已於香港上市，市值約 50 億美元。
創辦人暨首席科學長 — 鄭重(Leo), PhD
鄭博士畢業於北京清華大學，擁有超過 24 年生命科學研究經驗，曾任美國賓夕法尼亞大學牙醫學院研究助理教授。鄭博士是 9 件美國專利與 4 件國際專利的發明人，另有 10 件專利申請中，其中多項與 Saint Therapeutics 專利技術相關。 鄭博士已發表多篇高影響力論文，研究纖維調節蛋白（fibromodulin, FMOD）在細胞機制與瘢痕抑制上的作用，並率先研發出 FMOD 衍生胜肽 SLI-F06 以促進傷口癒合。 鄭博士擔任多項美國國家衛生研究院（NIH）及小型企業創新研究（SBIR）計畫負責人，累積獲得多項國家級與產學合作研究獎助金。包括：一項第二期小企業創新研究計畫（SBIR）資助、一項直進第二期 SBIR 資助、兩項快速通道 SBIR 資助、兩項 SBIR 商業化準備試點（CRP）計畫資助、一項牙科、口腔與顱顏組織器官再生中心（C-DOCTOR）跨領域轉譯專案（ITP）團隊獎助、一項整形外科基金會（PSF）轉譯研究獎助、一項 PSF 國家捐贈計畫資助，以及一項針對傷口癒合產品開發的 NIH R03 資助。 此外，鄭博士通過多項專業認證，獲得包括由 Center for Professionals Innovation & Education Inc. 所頒發的「藥物開發流程：從發現到商業化」、「製藥開發」證書，以及由 NIH 臨床研究辦公室頒發的「臨床研究原則與實務導論」與「臨床藥理學原則」證書。
Vice President, Corporate Development — Elissa Chou, PhD
Dr. Chou brings over 12 years of experience in corporate development, business development, strategic planning, and program management across pharmaceutical and biotechnology sectors. Her experience spans market research and competitive intelligence, opportunity screening, asset and technology evaluation, due diligence, financial modeling, and term sheet and agreement drafting and negotiation. Prior to Saint Therapeutics, Dr. Chou held roles spanning healthcare analytics and commercial strategy at Alere Health, translational program incubation and project management at SPARK Taiwan, corporate and business development at Allianz Pharmascience, and project scouting and evaluation in novel therapeutics for an angel fund. At Saint Therapeutics, her work focuses on fundraising, partnership development, and commercial strategy for the company's scar prevention and wound healing platforms. Dr. Chou holds a Ph.D. in Bioinformatics from Georgia Institute of Technology and degrees in Clinical Pharmacy and Pharmacy from National Taiwan University.
Head of Internal Audit — Nathan Hsu
Mr. Hsu graduated from Fontbonne University in the United States, where he earned double master’s degrees in Accounting and Business Administration. He also holds a Certified Internal Auditor. Mr. Hsu has over 15 years of experience in internal and external audit, internal control, regulatory compliance, risk management, and IPO-related practices. He has held positions at Deloitte, TaiDoc Technology, Asia Cement, UNIVA, and LINE Pay, spanning multinational corporations and publicly listed companies. Throughout his career, he has led the establishment and enhancement of internal control systems for Taiwanese and multinational companies, and has participated in IPO projects in Taiwan’s capital market, assisting companies in pre-listing internal control implementation, regulatory compliance, risk management, and corporate governance planning. He currently serves as Head of Internal Audit at Saint Therapeutics, where he is primarily responsible for supporting the establishment of the company’s internal control system, strengthening regulatory compliance and risk management mechanisms, and advancing IPO-related preparation initiatives.
Board Chair — Leon Soo
Mr. Soo holds an MBA from the Wharton School of the University of Pennsylvania and previously served as a Strategy and Operations Consultant with Deloitte Consulting in the United States. He currently serves as a board director of Hotai Motor Co. (TAIEX #2207) and other leading corporations across Taiwan and China.With extensive experience in the governance and management of Taiwan's publicly listed companies, Mr. Soo brings deep expertise in corporate strategy, organizational leadership, and business operations. He will provide valuable management insight and play a pivotal role in the Company's strategic planning and long-term development initiatives.
Board Member — Audrey Tseng
Ms. Tseng is the Honorary Vice Chairperson of PwC Taiwan and a distinguished CPA with over four decades of experience in capital markets, corporate governance, and biotechnology industry development. She has advised numerous biotech and healthcare companies on financing, IPOs, and strategic growth, and currently serves on the boards and investment committees of several life sciences companies and venture capital funds. Her expertise provides valuable leadership in governance, capital strategy, and long-term value creation.
Strategic Advisor — Dr. Monica Bey
Dr. Bey is a seasoned biotechnology executive, ecosystem builder, and ICF-certified coach with more than 20 years of experience spanning clinical development, medical affairs, technology transfer, venture investment, business development, and startup incubation.She currently serves as Strategic Advisor to Saint Therapeutics , where she supports corporate strategy, business development, organizational alignment, fundraising preparation, and long-term IPO readiness initiatives.Prior to joining Saint Therapeutics, Dr. Bey served as Deputy CEO of the Innovation Incubation Center at BioHub Taiwan, Academia Sinica , where she played a key role in advancing Taiwan’s biomedical innovation ecosystem and fostering collaborations among academia, startups, investors, and industry leaders.Earlier in her career, she held leadership positions across biotechnology companies, innovation platforms, and clinical development organizations, with expertise in strategic partnerships, technology commercialization, clinical operations, regulatory strategy, and biotech investment evaluation.Dr. Bey received her Ph.D. in Genetics from National Yang-Ming University and earned an EMBA in Technology & Innovation Management from National Chengchi University. She is also an ICF Associate Certified Coach (ACC), with a strong passion for leadership development, organizational communication, and team alignment.
